Facebook
X
LinkedIn
ForwardPractical Radiation Oncology Program 2025
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a strategic dialogue with the ASTRO CEO and a radiation oncology practice overview.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, radiation dosimetrists, physicists, pathologists, residents, neurosurgeons, diagnostic radiologists, radiation therapists, practice managers and allied healthcare professionals.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Discuss radiation and reconstructive surgery treatment options for patients with recurrent breast cancer.
- Discuss indications for hypofractionated radiation in post-mastectomy patients.
- Determine which patients would benefit from re-irradiation of their primary or secondary brain tumor.
- Assess the various radiation techniques, technology and fractionation to optimally benefit patients while mitigating risk of toxicity.
- Analyze strategies to manage toxicities that may develop from re-irradiation.
- Discuss the role of stereotactic body radiation therapy (SBRT) in managing non-spinal bone metastases, identifying key indications and expected outcomes.
- Discuss the role of prophylactic radiation therapy to prevent skeletal-related events.
- Evaluate supporting data that justifies the use of RT in various clinical situations and develop effective communication strategies for peer-to-peer interactions regarding treatment approval, as well as alternative treatment strategies.
- Understand the basics regarding circulating tumor DNA (ctDNA) and liquid biopsy technologies and applications.
- Understand the utility of ctDNA for noninvasive genotyping, early cancer detection, and minimal residual disease detection and monitoring.
- Actively engage with ASTRO leadership.
- Participate in ASTRO educational activities.
- Implement meaningful workflow changes in their practice to ensure appropriate billing capture.
- Enhance staff and electronic resource utilization to improve patient care and fulfill compliance needs.
- Identify ways to advocate for broader economic changes in favor of supporting community radiation oncology practices.
- Differentiate patients that are appropriate for radiation therapy and which of these patients may benefit for ultra low dosing.
- Understand the toxicity reduction efforts with the various tools at our disposal including dose considerations and techniques.
- Explain the steps in evaluation of a patient with an unknown primary p16 positive head and neck squamous cell carcinoma and management of patients where primary site is not identified.
- Discuss the role of TTMV-HPV DNA as a surveillance tool for patients with p16 positive head and neck squamous cell carcinoma.
- Describe management options for patients with oligometastatic p16 positive head and neck squamous cell carcinoma.
- To understand practical considerations for safely treating and escalating radiation dose to tumors in the upper abdomen.
- To increase awareness of trials of radiation therapy in liver and pancreatic cancer.
- Share practical tips for patient selection, treatment and response evaluation for radiation therapy.
- Approach a patient with oligometastatic cervical and endometrial cancer with a strategy that expands upon palliation.
- Consider the approach to reirradiation for patients with GYN malignancies.
- Explain pros and cons of different local therapies for early stage cSCCa.
- Determine appropriate work up, treatment volumes and doses of radiation therapy for adjuvant treatment of cSCCa.
- Identify the role and benefit of therapy in advanced stage disease of cSCCa.
The program is comprised of eleven sessions:
- Challenges in Breast Cancer Management: Recurrent Disease, Reconstruction and Hypofractionation
- Radiation Treatment of Recurrent Breast Cancer - Jose Bazan, MD, MS
- Reconstructive Surgery and Recurrent Breast Cancer - David Chang, MD
- Hypofractionation in Post-mastectomy Patients - Rinaa Punglia, MD, FASTRO, MPH
- Beyond the First Dose: Re-irradiation for Brain Tumors - Maximizing Outcomes and Managing Risk
- Re-irradiation of Primary Brain Tumors - Tips and Techniques - Daniel Trifiletti, MD
- Re-irradiation of Brain Metastases: When and How - Joshua Palmer, MD
- Mitigation and Management of Toxicity in the Re-irradiation of Brain Tumors - Christina Cramer, MD
- Bones of Contention: Navigating Innovations in Real-World Management of Non-Spine Bone Metastases
- Targeting Precision: Harnessing SBRT for Non-Spinal Bone Metastases - Winston Vuong, MD
- Prophylactic Palliation: Radiation Asymptomatic Bone Metastases as the Evidence Still Emerges - Jonathan Yang, MD, PhD
- Navigating the Maze: SBRT Advocacy, Retreatment Strategies and Alternative Approaches - Zachary Kohutek, MD, PhD
- Liquid Biopsies in Cancer
- ctDNA for Blood-based Noninvasive Genotyping - Scott Bratman, MD, PhD
- Liquid Biopsy Early Detection of Cancer - Aadel Chaudhuri, MD, PhD
- Liquid Biopsies for Detection of Minimal Residual Disease - Maximilian Diehn, MD, PhD
- Driving Engagement and Delivering Value: A Strategic Dialogue with ASTRO CEO
- Vivek Kavadi, MD, MBA, FASTRO
- Micro- and Macroeconomics of Radiation Oncology Practice
- Billing 101 - Christopher Jahraus, MD, FASTRO
- Clinicial Workflow: How the Structure of your Practice Can Cost You - Beant Gill, MD
- Alternative Payment Models and Economic Changes on the Horizon - Catheryn Yashar, MD, FASTRO
- Indolent Lymphomas: Radiation Oncology Considerations
- Nuts and Bolts of Indolent Lymphomas (clinicopathology, staging, prognosis) - Yolanda Tseng, MD
- Toxicity Reduction Efforts with Radiation Therapy - Chelsea Pinnix, MD, PhD
- Who and When - Indications for RT - Ari Wijetunga, MD, PhD, MS
- The Journey of the Unknown Primary in the HPV Era: Evaluation, Treatment, Surveillance and Management of Oligometastatic Disease
- Workup and Treatment of Unknown Primary p16 Positive Head and Neck Cancer Squamous Cell Carcinoma - Jessica Lee, MD
- Surveillance of p16 Positive Head and Neck Squamous Cell Carcinoma: Examination, Imaging, and Biomarkers - Edina Wang, MD
- Management of Oligometastatic Head and Neck Cancers in the Era of HPV - Musaddig Awan, MD
- Precision Radiotherapy for Liver and Pancreatic Malignancies: Indications, Techniques and Response Evaluation
- Ablative Radiation Therapy for Locally Advanced Pancreas Cancer: Clinical Indications and Practical Considerations - Michael Chuong, MD
- Integrating Radiotherapy into Multidisciplinary Care for Hepatocellular Carcinoma - Nina Sanford, MD
- Post Radiotherapy Imaging and Response Evaluation in Hepatobiliary Cancer/Metastases - Smith Apisarnthanarax, MD
- Practical Management Strategies for Advanced Stage Gynecologic Cancer Patients
- Radiotherapy Across the Spectrum of Metastatic GYN Malignancies - Kevin Albuquerque, MD
- Salvaging the Primary: Definitive Reirradiation or Palliation? - Dominique Rash, MD
- Management of Sexual Side Effects of Radiotherapy and Progressive Disease for the Advanced Stage Patient - Sage Bolte, PhD
- Reviving the Value of Radiation Therapy in Cutaneous Squamous Cell Carcinoma (cSCCa): From Early to Late Stage Disease and Everything in Between
- The Role of Definitive Radiation for Early Stage cSCCa - Shauna Campbell, DO
- The Role of Adjuvant Radiation in cSCCa - Lisa McGee, MD
- Practical Updates in Systemic Therapy for Locally Advanced Cutaneous SCC: Peri-Operative Immunotherapy, Chemoradiation, and Immunotherapy-Radiation Combinations - Jeremy Harris, MD, MPhil
This activity is available from December 1, 2025, through 11:59 p.m. Eastern time on December 31, 2026.
This activity was originally recorded at the 2025 ASTRO Annual Meeting.
PRO 01 - Challenges in Breast Cancer Management: Recurrent Disease, Reconstruction and Hypofractionation
- Christine S. Chung, MD, FASTRO, MPH, is employed by John Muir Medical Center and University of California San Francisco.
- Jose G. Bazan, Jr., MD, MS, is employed by City of Hope National Medical Center. Dr. Bazan receives honoraria as a member of the ASTRO VA Breast Panel.
- David S. Chang, MD, is employed by Kind/Chang Plastic Surgery.
- Rinaa S. Punglia, MD, FASTRO, MPH, is employed by Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center.
PRO 02 - Beyond the First Dose: Re-irradiation for Brain Tumors - Maximizing Outcomes and Minimizing Risk
- Stuart H. Burri, MD, is employed by Southeast Radiation Oncology Group. Dr. Burri has ownership equity in Charlotte Physics Holding, FUSE Oncology Holding, Oncology Practice Solutions, Radiation Oncology Centers of the Carolinas and Southeast Radiation Oncology Group.
- Daniel M. Trifiletti, MD, is employed by Mayo Clinic Jacksonville. Dr. Trifiletti receives honoraria from AFX-medical, Sevier pharmaceuticals and Boston Scientific. Dr. Trifiletti receives grant/research funding from Varian.
- Joshua David Palmer, MD, is employed by The Ohio State University Wexner Medical Center. Dr. Palmer receives honoraria from ICOTEC, Varian Medical Systems and Carbofix. Dr. Palmer receives grant/research funding from The Ohio State University.
- Christina Kehl Cramer, MD, is employed by Wake Forest University School of Medicine.
PRO 03 - Bones of Contention: Navigating Innovations in Real-World Management of Non-Spine Bone Metastases
- Christopher Hays Pope, MD, is employed by CARTI.
- Winston Vuong, MD, is employed by UW Medicine.
- Jonathan T. Yang, MD, PhD, is employed by New York University School of Medicine. Dr. Yang receives grant/research funding and compensation from AstraZeneca, Cantex Therapeutics, Debiopharm, Kazia Therapeutics, Nanocan Therapeutics and Plus Therapeutics. Dr. Yang owns stock options in Nanocan Therapeutics.
- Zachary A. Kohutek, MD, PhD, is employed by Vanderbilt University Medical Center.
PRO 04 - Liquid Biopsies in Cancer
- Aadel A. Chaudhuri, MD, PhD, is employed by Mayo Clinic Rochester. Dr. Chaudhuri receives compensation/payment from AlphaSights, AstraZeneca, Daiichi Sankyo, DeciBio, Guidepoint, Illumina, Roche and Tempus Labs. Dr. Chaudhuri owns stock in Geneoscopy. Dr. Chaudhuri has ownership equity in Droplet Biosciences and LiquidCell Dx, Inc.
- Scott V. Bratman, MD, PhD, is employed by Princess Margaret Cancer Centre, University Health Network and Adela, Inc. Dr. Bratman owns a copyright/patent with Adela, Inc and Roche.
- Maximilian Diehn, MD, PhD, is employed by Stanford Cancer Institute and Kaiser Permanente. Dr. Diehn receives honoraria, salary support and grant/research funding from AstraZeneca. Dr. Diehn receives honoraria and owns stock options in Gritstone Bio. Dr. Diehn has ownership equity in CiberMed, Foresight Diagnostics and Perception Medicine. Dr. Diehn receives royalties from a patent with Roche.
- Abhijit A. Patel, MD, PhD, is employed by Yale University School of Medicine. Dr. Patel receives compensation/payment from NuProbe and Biostate AI. Dr. Patel owns equity, copyright/patent/royalties and stock in Binary Genomics and receives grant/research funding from AstraZeneca.
PRO 05 - Driving Engagement and Delivering Value: A Strategic Dialogue with ASTRO CEO
- Vivek S. Kavadi, MD, MBA, FASTRO, is employed by ASTRO.
PRO 06 - Micro- and Macroeconomics of Radiation Oncology Practice
- Beant Singh Gill, MD, is employed by Associates in Radiation Medicine.
- Christopher D. Jahraus, MD, is employed by Generations Radiotherapy and Oncology PC.
- Catheryn M. Yashar, MD, FASTRO, is employed by University of California San Diego.
PRO 07 - Indolent Lymphomas: Radiation Oncology Considerations
- Sanjeev Aggarwal, MD, is employed by UVA Community Health. Dr. Aggarwal receives travel expenses and compensation from Evolent Health. Dr. Aggarwal owns stock in Astrazeneca, AVDL, AXSM, Interra Neuroscience, iPath and Zeto, Inc.
- Yolanda D. Tseng, MD, is employed by University of Washington/Fred Hutchinson Cancer Center.
- Chelsea C. Pinnix, MD, PhD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Pinnix receives grant/research funding from Merck.
- Ari Wijetunga, MD, PhD, MS, is employed by University of North Carolina.
PRO 08 - The Journey of the Unknown Primary in the HPV Era: Evaluation, Treatment, Surveillance and Management of Oligometastatic Disease
- Virginia M. Diavolitsis, MD, is employed by Riverside Radiation Oncology, Inc. and The Ohio State University.
- Jessica Wen-chia Lee, MD, is employed by Duke University Medical Center.
- Edina Cindy Wang, MD, is employed by Duke University Medical Center.
- Musaddiq Javvad Awan, MD, is employed by Medical College of Wisconsin. Dr. Awan receives grant/research funding from Genentech and the NIH.
PRO 09 - Precision Radiotherapy for Liver and Pancreatic Malignancies: Indications, Techniques and Response Evaluation
- Michael David Chuong, MD, is employed by Miami Cancer Institute, Baptist Health South Florida. Dr. Chuong receives grant/research funding from Novocure.
- Nina N. Sanford, MD, is employed by UT Southwestern Medical Center.
- Smith Apisarnthanarax, MD, is employed by University of Washington/Fred Hutchinson Cancer Center.
- Najeeb Mohideen, MD, FASTRO, is employed by Northwest Community Hospital.
PRO 10 - Practical Management Strategies for Advanced Stage Gynecologic Cancer Patients
- Avani Dholakia Rao, MD, is employed by Inova Schar Cancer Institute. Dr. Rao receives grant/research funding from Ion Beam Applications.
- Kevin V. Albuquerque, MD, is employed by University of Texas Southwestern Medical Center. Dr. Albuquerque receives honoraria, travel expenses and compensation from ACR and Elsevier Clinical Path.
- Dominique L. Rash, MD, is employed by University of California San Diego.
- Sage Bolte, PhD, is employed by INOVA Health Foundation.
PRO 11 - Reviving the Value of Radiation Therapy in Cutaneous Squamous Cell Carcinoma (cSCCa): From Early to Late Stage Disease and Everything in Between
- Arshin Sheybani, MD, is employed by Iowa-Wide Oncology Research Coalition NCORP
- Shauna Rosalie Campbell, DO, is employed by Cleveland Clinic.
- Lisa A. McGee, MD, is employed by Mayo Clinic.
- Jeremy P. Harris, MD, MPhil, is employed by University of California Irvine. Dr. Harris receives travel expenses and compensation from Novocure.
Planners:
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
Available Credit
- 12.50 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 12.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 12.50 Certificate of AttendanceThis activity was designated for 12.50 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
Nonmember: $849
Member: $699
Postdoctoral Fellow Member: $349
Member-in-Training: $349
Student/Grad Student/PGY-1 Member: $349
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those registrants. Including those who for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement
The course and its materials will only be available on the ASTRO website until December 31, 2026, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.